文献速递细胞病理与分子病理神经与头颈病理

分化型高级别甲状腺癌的细胞学特征:40例多中心研究

Cytologic features of differentiated high-grade thyroid carcinoma: A multi-institutional study of 40 cases.
PubMed 文献 · Cancer Cytopathol · 2024-06-14

本研究回顾6家机构10年间40例经切除确诊的分化型高级别甲状腺癌(DHGTC)的细针穿刺(FNA)细胞学特征。多数FNA为Bethesda IV类及以上,但细胞学对DHGTC敏感性低;约25%病例出现显著细胞异型性、核大小不一、大卵圆核、核分裂或坏死,68%伴高危分子改变,TERT突变占41%。

要点

  • DHGTC的FNA多归类为Bethesda IV类及以上,但细胞学诊断敏感性低。
  • 约25%DHGTC显示显著细胞异型、核大小不一、大卵圆核、核分裂或坏死。
  • 68%DHGTC伴高危分子改变,TERT突变占41%且多合并RAS或BRAF p.V600E。

核心结论

  • 细胞学对DHGTC敏感性低,但部分病例细胞学特征提示高级别甲状腺癌可能。
  • DHGTC常伴高危分子改变及老年、较大病灶等临床病理特征。

研究设计与样本

  • 多中心回顾性研究,检索6家机构10年(2013-2023)病理档案。
  • 纳入40例经切除确诊为DHGTC且有 prior FNA 的病例,评估32项细胞形态学特征。

主要发现

  • 患者平均年龄64.2岁,平均病灶大小4.9 cm,95.2%病例TI-RADS评分为4或5。
  • 组织学亚型:乳头状癌65%、滤泡癌22.5%、嗜酸细胞癌12.5%。
  • 超过97%的FNA病例为Bethesda IV类及以上。
  • 约25%DHGTC显示显著细胞异型性、核大小不一增加、大卵圆核、核分裂活性或坏死(p < .05)。
  • 68%DHGTC伴高危分子改变;TERT突变占41%,其中89%伴第二突变(通常RAS或BRAF p.V600E)。

关键数值与推荐

  • DHGTC定义依据WHO标准:保留高分化滤泡细胞来源肿瘤的结构和/或细胞学特征,同时具有高级别特征。
  • 细胞学特征评估包括显著细胞异型性、核大小不一增加、大卵圆核、核分裂活性或坏死,约25%病例阳性(p < .05)。

临床怎么用

  • FNA诊断为Bethesda IV类及以上时,若见显著细胞异型、核大小不一、大卵圆核、核分裂或坏死,应警惕DHGTC可能。
  • 对高危分子改变(如TERT突变合并RAS或BRAF p.V600E)及老年、大病灶患者,需结合细胞学与分子结果综合评估。

局限性

  • 回顾性多中心研究,样本量40例,可能存在选择偏倚。
  • 细胞学对DHGTC敏感性低,部分病例缺乏特异性细胞形态学特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Differentiated high-grade thyroid carcinoma (DHGTC) is recently recognized by the World Health Organization (WHO) as a subgroup of thyroid carcinomas with high-grade features while retaining the architectural and/or cytologic features of well-differentiated follicular-cell-derived tumors. The cytomorphology of DHGTC is not well documented despite potential implications for patient triage and management. METHODS: The pathology archives of six institutions were searched for cases diagnosed on resection as "high-grade thyroid carcinoma" using WHO criteria. The fine-needle aspiration (FNA) cohort represents a 10-year period (2013-2023); all were reviewed to confirm DHGTC classification. The corresponding FNAs were assessed for 32 cytomorphologic features. RESULTS: Forty cases of DHGTC with prior FNA were identified. The mean patient age was 64.2 years. The average lesion size was 4.9 cm, and the majority demonstrated a TI-RADS score of 4 or 5 (95.2%). Three main high-grade subsets of DHGTC based on corresponding histology included papillary thyroid carcinoma (65%), follicular carcinoma (22.5%), and oncocytic carcinoma (12.5%). Over 97% of FNA cases were classified as Bethesda category IV or above. Approximately 25% of DHGTC showed cytologic features that included marked cytologic atypia, increased anisonucleosis, large oval nuclei, mitotic activity, or necrosis (p < .05); 68% of DHGTC cases were associated with high-risk molecular alterations. TERT mutations occurred in 41%, of which 89% of these were associated with a second mutation, usually RAS or BRAF p.V600E. CONCLUSIONS: Cytology has a low sensitivity for DHGTC, although a subset of DHGTCs have cytologic features raising the possibility of a high-grade thyroid carcinoma. Other findings include high-risk molecular changes and clinicopathologic features such as older patient age and larger lesion size.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Torous VF, Jitpasutham T, Baloch Z, et al. Cytologic features of differentiated high-grade thyroid carcinoma: A multi-institutional study of 40 cases. Cancer Cytopathol. 2024. PMID: 38873907. doi:10.1002/cncy.22874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。